Table 1.
Baseline demographic and clinical characteristics of the full Work Productivity and Activity Impairment questionnaire-respondent cohort
| Baseline demographic and clinical characteristics | Ocrelizumab (n = 90) | Oral DMTs (n = 316) | Injectable DMTs (n = 224) | p value |
|---|---|---|---|---|
| Age, years (mean ± SD) | 44 ± 9.6 | 41 ± 11 | 43 ± 12 | 0.02 |
| Female sex, n (%) | 61 (68) | 191 (60) | 141 (63) | 0.44 |
| Education, n (%) | 0.57 | |||
| Greater than high school | 76 (84) | 253 (80) | 185 (83) | |
| High school or less | 14 (16) | 63 (20) | 39 (17) | |
| Line of therapy, n (%) | < 0.01 | |||
| ≥ 2 | 78 (87) | 139 (44) | 60 (27) | |
| 0–1 | 12 (13) | 177 (56) | 164 (73) | |
| Disease subtype, n (%) | < 0.01 | |||
| RRMS | 73 (81) | 303 (96) | 211 (94) | |
| SPMS | 17 (19) | 13 (4) | 13 (6) | |
| EDSS score at treatment initiation, n (%) | < 0.01 | |||
| ≥ 3 | 46 (51) | 47 (15) | 33 (15) | |
| 0–2 | 44 (49) | 269 (85) | 191 (85) | |
| Years since diagnosis (mean ± SD) | 6.1 ± 5.3 | 4.9 ± 5.3 | 6.5 ± 6.4 | < 0.01 |
| Years on current therapy, n (%) | < 0.01 | |||
| ≥ 1 | 39 (43) | 283 (90) | 205 (92) | |
| < 1 | 51 (57) | 33 (10) | 19 (8) |
DMTs Disease-modifying therapies, EDSS Expanded Disability Status Scale, RRMS relapsing–remitting multiple sclerosis, SD standard deviation, SPMS secondary progressive multiple sclerosis